tiprankstipranks
Trending News
More News >
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (HK:2315)
:2315
Hong Kong Market

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (2315) Revenue

Compare
1 Followers

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Revenue

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H had a revenue of 620.96M in the quarter ending Jun 30, 2025, with 8.95%. This bring the company's revenue in the last twelve months to 1.19B, Decreased 21.47%. In the fiscal year ending Dec 31, 2024, Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H had annual revenue of 980.45M with 36.76% growth.
Revenue (ttm)
1.19B
Revenue Growth
48.38%
P/S Ratio
10.43
Revenue/Employee
HK$877,756
Employees
1,117
Market Cap
HK$10.22B

Revenue Chart

Revenue History
Fiscal End Date
Revenue
Change
Growth
Dec 31, 2024
980.45M263.54M+136.76%
Dec 31, 2023
716.91M183.03M+134.28%
Dec 31, 2022
533.88M179.33M+150.58%
Dec 31, 2021
354.56M101.01M+139.84%
Dec 31, 2020
253.54M